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Abstract 
  Schistosomiasis is a parasitic disease that causes considerable socio-economic 
losses in affected areas due to loss of productive capacity of affected individuals and 
high rates of morbidity and mortality.    
  Therapeutic controls for this parasitic disease have shown some drawbacks with   
resistance emergence to praziquantel, the drug of choice for treatment, being reported 
in recent years. Thus, new chemotherapeutic targets are been investigated, aiming to 
develop drugs that are more effective, with lower cost and fewer adverse reactions. 
Among these new targets, aspartic proteases are among the most promising, since their 
involvement in other diseases such as Alzheimer's and diabetes have been proven and 
a chemotherapeutic arsenal for AIDS treatment has been developed based on the 
structure and function of the HIV1 aspartic protease. The rational design of new drugs 
requires knowledge of the structures of target proteins.    
  In this study we have examined the activation of pro-enzyme, recombinant forms 
of two putative cathepsin D-like aspartic proteases from the helminth Schistosoma 
mansonii (SmCDs).  Extensive folding trials were undertaken in attempts to determine 
the potential for activation of the proteolytic activities of the enzymes.  A recombinant 
protein disulfide isomerase from the same organism was also prepared for use in 
protease folding trials. Preliminary evidence suggests that an activated form of one of 
the two proteases (SmCD2) may be obtained by introducing a solubilizing maltose-
binding tag on the N-terminal end resulting in soluble expression of the enzyme. This 
result has raised the prospect of developing an in vitro screening tool to identify 
potential lead compounds for new drug development. Although PDI samples were 
purified and active in rearrange disulfide bridges of insulin, no evidence of assistance in 
refolding SmCDs were observed. Since PDI itself may be considered as a drug target, 
crystallization attempts in order to obtain its structures were done. Both crystallization of 
PDI and its influence in SmCDs refolding must be further be investigated in different 
conditions. 

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Chapter 1- Schistosomiasis 
1A- Schistosomiasis and drug discovery. 
  According to the World Health Organization (WHO-UN), parasitic diseases such 
as malaria and schistosomiasis are a major focus of public health concern in developing 
countries. Most are classified as neglected diseases because of the lower interest of 
pharmaceutical industries in development of treatments. (Fenwick et al., 2003; Renslo, 
2006).  
   Adaptation of transmission cycles of neglected diseases to new 
geographical areas (Figure 1), climate changes and human migration, limitations of 
treatment availability (economic and / or high toxicity and / or reports of resistance) are 
factors that drive the search for new forms of therapies, especially considering newly 
acquired structure/function relations of vital proteins for parasite metabolism, such as 
proteases, chaperones and outer membrane channels. (Reithinger et al., 2006; Renslo, 
2006). 
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Figure 1: Upper panel: Distribution of schistosomiasis (Engels et al,2002); Lower 
panel, male and female parasite and patient with schistosomiasis 
(www.shedfoundation.org) 
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Figure 2: The Schistosoma life cycle: eggs are eliminated with feces or urine (1). 
Under optimal conditions the eggs hatch and release miracidia (2), which swim and 
penetrate snail intermediate hosts (3). The stages in the snail include 2 generations of 
sporocysts (4) and the production of cercariae (5). Upon release from the snail, the 
infective cercariae swim, penetrate the skin of the human host (6), and become 
schistosomulae (7). The schistosomulae migrate through several tissues to their 
residence site (8, 9). Adult worms in humans reside in the mesenteric venules in various 
locations (10).  S. japonicum is more frequently found in the small intestine (A), and S. 
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mansoni occurs more often in the large intestine (B). However, both species can occupy 
either location, and they are capable of moving between sites. Various animals, such as 
dogs, cats, rodents, pigs, horses and goats, serve as hosts (http://www.niaid.nih.gov). 
 Schistosomiasis is one of the major neglected tropical diseases, affecting 200 
million people in Latin America, North Africa, the Middle East, South China and 
Indochina. It is also known as barriga-dágua in Brazil or bilharzioses (tribute to Thomas 
Bilharz, who identified the parasites for the first time in 1851 in Egypt) and is caused by 
parasites of the genus Schistossoma (trematode). The main etiologic agents in humans 
are: S. mansoni (Africa and Latin America), S. haematobium (Africa and Middle East), 
S. japonicum (China and Philippines) and S. mekongi (Laos and Cambodia).  
 Control of Schistosomiasis is achieved through therapeutic administration of 
praziquantel and oxamniquin, drugs that are effective and present low toxicity and cost. 
However, schistosomiasis has been expanding in many regions and this seems to be 
associated with high rates of re-infection and repeated interventions that have limited 
the effectiveness of pharmacotherapy and allowed development of resistance to 
therapeutics. Because of the low number of alternatives to the drugs available and lack 
of a vaccine (Capron, 2005; Abdulla, 2007), the construction of a therapeutic arsenal 
against schistosomiasis is a major goal of public health authorities and scientists 
(Fenwick et al., 2003; Sibley & Hunt, 2003)  
The search for new drugs has focused on obtaining new molecular targets 
through a better knowledge of the biochemistry and metabolism of the parasite. 
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Substantial effort has been made to identify the complete genome, proteome and 
glycome of the Schistosoma genus by two independent groups, one Chinese and one 
Brazilian (Curwen et al., 2004; Verjovski-Almeida et al., 2004; McManus et al., 2004; 
Wilson et al., 2006).  
One of the most intriguing discoveries about the infective process of parasites is 
their use of proteases for degradation of host proteins in order to obtain amino acids for 
their metabolism. Not only do those proteases have cellular localizations and structural 
properties different from those existing in vertebrates, but also the degradation cascade 
that occurs is quite different: In vertebrates, it involves several proteases in a 
coordinated manner (especially serine proteases), but in invertebrates, degradation 
events appear to be non coordinated and functionally redundant, with cysteine and 
aspartic proteases cleaving the same substrate (Delcroix et al., 2006). This creates the 
prospect of developing libraries of inhibitors targeting protease functions that could be 
used against some vital aspect of the host-parasite relationship, such as degradation of 
host proteins as a source of amino acids for parasite development (Renslo & McKerrow, 
2006).  
Historically, studies about therapies based on the structure of aspartic proteases 
began with HIV-1 protease and renin and led to a series of new drugs based on statin, 
such as AG-1343 designed as an inhibitor for HIV1 protease (Kaldor et al., 1997) 
(Figure 3). Other studies with  different aspartic proteases are currently being made in 
order to repeat this success and achieve new chemotherapeutics: (i) BACE-1 (Β 
amyloid precursor protein-cleaving enzyme 1), involved in accumulation of amyloid 
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forms in the brain, causing Alzheimer's disease; (ii) Cathepsin E, protein present in the 
rough endoplasmic reticulum involved in processing major histocompatibility complex 
class II (MHC-II) and the endothelial vasoconstrictor peptide, in addition to having a 
possibly important role in cerebral ischemia; (iii) Cathepsin D, whose over-expression is 
found in cancerous tissues.  
 
Figure 3: Interaction of AG-1343 with HIV-1 protease: A: View perpendicular, 
showing the concealment of inhibitor, B: Perpendicular view of the region covering the 
inhibitor-protein interaction, C: View of the top of the molecule, D: Surface subsites of 
the S1 (adapted from Silva-Jr & De Simone, 2005).  
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Exploration of Schistosoma aspartic protease function as a drug target originally 
started with the report by Becker et al. (1995) of a cDNA sequence of S. japonicum 
aspartic protease zymogen of 380 amino acid residues with 50-55% identity with the 
human cathepsin D (here called SjCD1). Through alignment with other enzymes, 
Becker et al. proposed an enzyme that has a mature form with 329 amino acid residues 
and 36kDa. Analysis of Southern blots allowed the same authors to infer that this gene 
would be in a single copy in S. japonicum and should be present in S. mansoni as well. 
In fact, Wong et al. (1997) reported the discovery of a putative aspartic protease from 
screening of cDNA libraries of the adult worms of S. mansoni.  
This sequence (here called SmCD1) codes for an enzyme with 50-55% identity 
with other orthologous enzymes. The importance of these proteases for the parasite lies 
in the possibility that they have a broad spectrum of substrates, from proteins involved 
in the immune system as IgG and proteins of the complement system (Verity et al., 
2002), serum albumin and hemoglobin. This could infer a role for aspartic proteases in 
defense of the parasite against the host immune system in addition to their use in the 
metabolism of amino acids.   
  Interestingly, S. japonicum’s AP has 3 different cleavage sites for human 
hemoglobin than the human cathepsin D orthologue while S. mansoni’s AP has 15 
different sites (Brindley et al., 2001) and structures obtained in silico through molecular 
modeling by homology of SmCD1 showed similarities to HIV-1 protease and some 
differences to its human counterpart enzyme, cathepsin D (Silva-Jr et al., 2002). 
SmCD1 does not present a loop between residues L94 and G95 and a C-terminal 
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protuberance affecting the binding the substrate as human cathepsin D. Besides that, 
SmCD1 and human cathepsin D seem to have different volumes and surface 
electrostatic potentials in the binding subsites, according to diferences in the amino acid 
residue composition. These findings can open the path for development of antiretroviral 
drugs for anti-schistosomiasis therapy (Silva-Jr et al., 2002).  
            The aspartic proteases of Schistossoma spp have more functional and structural 
similarities with bovine cathepsin D, than with human cathepsin D (e.g. common 
epitopes found in the SmCD1 and in the bovine enzyme, but not in human cathepsin D) 
which could be interesting for future immunodiagnostic and drug discovery applications 
(Valdivieso et al., 2003), although it’s potential as a vaccine was considered modest 
(Verity et al., 2002).  
 Families of genes of APs have been described in different groups of eukaryotic 
life forms, including the Apicomplexa parasite Plasmodium sp. (Jean et al., 2001) and 
Toxoplasma gondii (Shea et al., 2007), the nematode Caenorhabditis elegans 
(Tcherepanova et al., 2000) and Onchocerca volvulus (Jolodar & Miller, 1998). 
Therefore, it was not entirely surprising when the first results of  transcriptome project of 
S. mansoni showed fragments of coding sequences of additional aspartyl proteases to 
SmCD1 (Merrick et al., 2003). Allied to this, a two-dimensional electrophoretic analysis 
(2DE) of an extract of adult worms linked to pepstatin-agarose, prepared at the 
Laboratory of Biochemistry of Proteins and Peptides (LBPP) of IOC / FIOCRUZ (Silva, 
Jr, 2005), revealed the presence of different protein species in the range of 36-50 kDa. 
Further research undertaken by the Brazilian group analyzing EST”s databanks of S. 
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mansoni indicated that a family of aspartyl proteases is present in this parasite (here 
collectively called SmAPs).   
  Over the past five years, efforts to characterize the new members of the aspartic 
protease family S.mansoni resulted in the complete sequencing of the cDNA of two new 
genes similar to Cathepsin D, which were named SmCD2 and SmCD3 (deposited in 
Genbank under numbers DQ256465 of access and EF373976, respectively). SmCD2 
has an open reading frame (ORF) of 1203 bp and genomic structure with 7 exons, 
similar to SmCD1, while SmCD3 has an ORF of 1161 bp, and has only 6 exons. Both 
genes encode pre-proenzymes of 401 and 387 amino acid residues respectively, and 
contain the signature D (T / S) G residues typical of the active site of aspartic proteases 
from the pepsin family. The computational analysis and sequence conservation 
suggests a signal peptide of 19 residues for SmCD2 and a propeptide of 43 amino acid 
residues covering residues 20-62. Similar analysis suggested SmCD3 has a signal 
peptide of 15 residues and pro-region covering residues 16-52. SmCD2 has 5 potential 
sites for N-glycosylation at aminoacid residues 32, 43, 198, 246 and 348, while SmCD3 
has only two sites at positions 54 and 136.  
Currently, therapeutic approaches based on RNA interference technology, a 
technique that can knock out AP genes in order to observe gene function in the 
parasite’s biology, led to opposite conclusions. Skelly et al. (2003) observed that the 
expression of the SmCD1 did not result in adverse effects on parasite growth cultivated 
in vitro, indicating that chemotherapy interventions need to consider the redundancy of 
protease functions involved in hemoglobin degradation. On the other hand, RNA 
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interference studies by Morales et al., 2008, suggest blockage of about 70 percent of 
the activity of the enzyme and a decrease in the rate of growth of S. mansoni, implying 
that degradation of hemoglobin would not be redundant. 
 
1A- aspartic proteases of the pepsin family (A1)               
Aspartic proteases, (APs), as all peptidases, catalyze the hydrolysis of peptide 
bonds, a fundamental chemical reaction in biology. Since APs are involved in a wide 
range of cellular, physiological and pathological processes (Eder et al., 2007; Turk, 
2006; Rawlings & Barret, 1993, 2000) these enzymes have been used in diverse 
industrial processes such as cheese and flavor enhancement compound production as 
well as new therapeutic research/production at pharmaceutical companies 
(Horimoto,2009). 
The electronic database MEROPS, (http://merops.sanger.ac.uk/), shows in its 
catalog seven clans of aspartic proteases, divided into 14 families, 3855 described 
sequences and 37 three-dimensional structures deposited in the PDB from fungi, plants, 
animals, bacteria, viruses, protozoa and archea. Although family A22 (preselinin-like) 
has gained increasing attention due to new discoveries associating these aspartic 
proteases to neurodegenerative diseases (Parks & Curtis, 2007), the most important 
families are A1 (pepsin-like family) and A2 (HIV1 aspartic protease-like family). Family 
A1 apparently originated from a gene duplication event related to adaptations to new 
function (Carginale et al., 2004), (Dunn, 2002). Table 1 summarizes the various 
biological functions and industrial applications of the family A1 enzymes. 
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Table 1-Biological and Biotechnological functions of AP family A1 enzymes 
Enzyme Function 
Pepsin Nutrition of vertebrates 
MemAPsin I Involved in Alzheimer's disease 
MemAPsin II Involved in Alzheimer's disease 
Cathepsin D Involved in cancer, inflammation, immune response, 
nutrition of parasites, apoptosys, autophagy 
Cathepsin E Involved in lysosomal disorders, cancer and immune 
response 
Renin Involved in blood pressure control 
Chymosin Involved in digestion of milk in neonates and production of 
cheese 
Plasmepsin I Nutrition of parasites (Plasmodium) 
Plasmepsin II Nutrition of parasites (Plasmodium) 
Gastricsin Nutrition of vertebrates 
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1B-Structure, folding and activity of aspartic proteases of  cathepsin D-like 
proteases 
1.B.1- General structure and Catalytic mechanism 
 Family A1 APs are very similar in terms of general structure, showing a high 
degree of structural homology with minor variations (Tyndall et al,2005). The secondary 
structure is entirely formed by β sheets with few α-helices and the tertiary structure 
shows the presence of two chains linked by a loop region known as a flap. The flap has 
greater structural flexibility and lays above the active site cleft (Koelsh, 1994; Dunn, 
2002). The molecular weight is generally around 35-45 kDa.  Despite these similarities, 
these APs have different functions and cellular localizations as shown in Table 1. 
 The catalytic site of aspartic proteases from the A1 family follows fundamental 
principles that guide the hydrolysis of peptide bonds such as the complementarity and 
electrostatic interaction between the surfaces of the proteins. The active sites of the 
protease are capable of accommodating a single sidechain of the substrate in surface 
clefts called subsites (Turk, 2006). Subsites are numbered S1-Sn towards the N-
terminal and S1'-Sn' towards the C-terminal, beginning from the subsites closer to the 
scissile bond. The substrate side chains accommodated in this subsite are named as 
P1-Pn and P1'-Pn in the same way previously described, as it can be seen in Figure 4 
(Turk, 2006). 
 The AP catalytic site is larger compared with other enzymes and forces the 
substrate to adopt an extended β strand conformation, stretching the substrate 
polypeptide in order to facilitate reaction (Dunn,2000; Tindall et al, 2005). The main 
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reason for such a conformation is that linear extension of the substrate polypeptide 
exposes maximally all the main chain amide atoms of the substrate to the solvent and 
protease residues inside the subsites (Tyndall et al, 2005). The correct solvation of the 
product as consequence of this arrangement prevents peptide bonding between 
substrate and product, driving the equilibrium for reaction toward product formation 
(Tyndall et al,2005). On the other hand, helix/turn structures are too large to bind 
correctly in the subsites pockets confirmed by the fact that proteases do not recognize 
these structures unless they are unfolded. Such conformational selection explains why 
the resistance of folded regions of some proteins leads to active site selectivity to 
proteolytic activity (Tyndall et al,2005).  
 In fact, this structural aspect can be one of several ways cells have to precisely 
control proteolytic activity in space and time, considering the high diversity of biological 
processes in which these enzymes are involved. Other ways can be: (i) via a cascade of 
enzyme activities; (ii) specific AP degradation (iii) blockade of proteolytic activity by 
natural inhibitors; (iv) influence of cellular compartmentalization and chemical 
microenvironment; (v) regulation of gene expression; and (vi) regulation by substrate 
and/or product inhibition or other chemical compounds (Lazure, 2002) 
The proposed reaction mechanism occurs in an acidic environment (pH 2-5), as 
shown in Figure 4 where the aspartic residue carboxyl group is in its acidic form and 
the other is in its basic form in the enzyme substrate complex. This arrangement 
activates a water molecule which then attacks the carbonyl carbon of the scissile bond, 
resulting in the formation of a tetrahedral geminal diol intermediate. Subsequently 
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deprotonation of the hydroxyl group occurs by one of the catalytic aspartates, with a 
simultaneous activation of the leaving amine by the other protonated aspartic residue, 
which leads to the peptide bond cleavage (Eder et al, 2007).  
 
 
 
Figure 4: Schematic representation of molecular recognition of proteases and 
the reaction mechanism of aspartic proteases. A) The surface of the protease able to 
accommodate the substrate is called subsite. Subsites are named as S1–Sn towards 
the N terminus of the substrate, and S1'–Sn' towards the C terminus, beginning from the 
scissile bond. The substrate residues they accommodate are named as P1–Pn, and 
P1'–Pn', respectively(adapted from Turk, 2006). ; B) Mechanism for the general acid-
base aspartic protease reaction: one aspartate residue activates a water molecule by 
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abstracting a proton. This enables water to attack the substrate scissile bond, 
generating an intermediate. Rearrangement of this intermediate leads to protonation of 
the scissile amide (adapted from Eder et al, 2007).      
1.B.2 Importance of the prosegment 
 All vertebrates and most of the fungal APs are synthesized as zymogens, 
inactive precursors of the active and mature enzyme. This prosegment occludes the 
active site from the rest of the enzyme through a very intimate non-covalent bonding, in 
the same way as the substrates do for conversion of zymogen to the mature form 
(Lazure, 2002). Different mechanistic models have been proposed and those are 
summarized by Koelsh et al (1994) as:  i) Complete self processing (pro-pepsin); ii) 
Partially self processing assisted by different proteins (lysosomal and vacuolar 
peptidases); and iii) Fully assisted processing (pro-renin). All of these mechanisms 
occur at acidic pH values so the disruption of electrostatic interactions can occur 
between the ~ 54 residue prosegment polypeptide and the rest of the enzyme (Horimoto 
et al, 2009). 
 AP prosegments can be divided into two types: Type 1, has the ability  to act as 
an intramolecular chaperone, lowering the energy barrier among folded and unfolded 
states or stabilizing the folded state in a kinetic way; Type 2: besides working as an 
intramolecular chaperone, the prosegment also performs other possible functions. This 
feature can be related to the fact that prosegment regions have fewer similarities than 
other AP enzyme parts.  (Fortenberry & Chigwin-1995). However, the prosegments of 
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Cathepsin D and Pepsin are able to interact with non-parental AP, suggesting common 
structural motifs (Fusek et al, 1991, Ma et al,2006). 
 In plasmepsin II, the prosegment seems to be very important for the 
correct folding and catalytic activity of this AP, since expression of the enzyme with a 
prosegment shorter than normal led to changes in the structure of the mature enzyme 
(Khan et al., 1999). Also a chimeric plasmepsin II with a pepsinogen prosegment fusion 
instead of the natural plasmepsin II prosegment showed instability and was considered 
misfolded (Horimoto et al, 2009). The zymogen conversion into the mature form seems 
to be different from other A1 aspartic proteases, since the prosegment of plasmepsin II 
associates with both C and N terminals to keep two domains apart from each other. This 
is considered a folding intermediate of the protein, once the lobes are assembled but 
not connected correctly due to charge repulsion of catalytic aspartates presented in this 
configuration. (Horimoto et al, 2009). 
Pepsin, a human digestive aspartic protease, has its precursos form 
(pepsinogen) converted to the mature form when the pH shift towards acid causes 
destabilization of salt bridges that maintain the prosegment in place. In addition, the 
prosegment acts in the correct folding of the mature form pepsin, lowering the free 
energy barrier and accelerating the folding process to a practical timescale (Dee et al, 
2009). In the cases of cathepsin D and cathepsin E, the prosegments may be involved 
in cellular localization and also can have different functions inside the cell (Horimoto et 
al, 2009) 
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1C- Expression and Refolding procedures for recombinant APs. 
The study of structure-function relationships has enabled advances in 
understanding the logic of life at the molecular level. Some of the techniques used in 
this field, such as X ray crystallography, small Angle X ray scattering (SAXS) and 
nuclear magnetic resonance (NMR) spectroscopy require large protein quantities in 
order to solve the structure (Minor, 2007). Therefore, many proteins have to be 
produced through recombinant DNA technology, often utilizing hosts with a cellular 
apparatus that may not resemble the original organism.  
SmCDs and related parasite proteins such as Necator americanus and 
Ancylostoma duodenale aspartic proteases (named respectively as Ac-APR-1 and Na-
APR-1) were previously expressed in insect cells. SmCDs, Ac-APR-1 and Na-APR-1 
genes were cloned into a pBacPak6 and co-transfected with baculovirus and SF9 insect 
cells. After generation of baculovirus stocks, Trichoplusia ni High Five cells were 
infected to express these aspartic proteases as secreted pro-enzymes. Those pro-
enzymes were purified successfully using pepstatin-affinity columns (Brindley et 
al.2001) and the enzymatic activity confirmed via degradation of hemoglobin, IgG, 
synthetic fluorogenic peptides, and human collagens (I, III, IV and V), canine and 
human serum albumin, and canine and human fibrinogen (Beyer & Dunn, 1996 ; 
Brindley et al. 2001, Verity et al, 2001 Willianson et al, 2003). However, Differences in 
proteins expressed by in baculovirus infected insect cells and original life forms have 
been described in some cases. For example, inefficient secretion from insect cells and 
improperly folded and/or glycosylated proteins, or low levels of expression. 
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 On the other side, SmCDs were not yet expressed in bacteria, although related 
aspartic proteases, such as human cathepsin D, Na-APR-1 and plasmepsin were 
already expressed in this heterolougous system (Ranjit et al, 2009 Pearson et al, 2010). 
E. coli is the main host for recombinant protein production due primarily to: (i) Modest 
nutritional requirements of the culture medium; (ii) Rapid accumulation of biomass; (iii) 
Tolerance of the fermentation process at high cell density; (iv) Process of scaling-up 
production is simple; and (v) Knowledge of E. coli cell physiology, molecular biology and 
metabolism. Some of the heterologous proteins are sometimes expressed in inactive 
and incorrectly folded form or even in a completely insoluble form known as inclusion 
bodies (Boney & Mujacic, 2004). Although the formation of inclusion bodies is 
interesting in terms of ease of purification steps from cell homogenates and protection 
from protease degradation, the process of solubilization and refolding is laborious and 
more often  leads to a lower fraction of active protein. 
Another major problem in refolding is the precise determination of what is the 
relevant protein activity to be assayed in order to evaluate the success of the refolding 
process. It is well known in modern protein folding theories that the polypeptide chains 
have plasticity and possible multifunctionality. This plasticity is due to the dynamic 
interaction of the polypeptide chain with microchemical and physical (temperature, 
pressure, volume, and viscosity) environments inside cellular and body compartments. 
This could lead to different functions for the same protein. Thus, a refolding procedure 
could make the protein achieve a different folding and function than those expected by 
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the scientist and, on the other hand, new possible functions could be not explored 
(Zhou, 2008, Shin et al, 2006 Frauenfelder et al, 2006, Dix, 2008). 
  Plasticity in function can be seen in human Cathepsin D, since its proteolitic 
activity is not the major reason of increased proliferation of cells in tumor tissues (Fusek 
and Vetvicka, 1994). The mitogenic function in vitro seems to be strictly connected to 
the use of procathepsin D and not the mature form, thus suggesting the importance of 
ligand binding activity of the polypeptide alongside the proteolysis function. Presence of 
pepstatin A into the sample tested did not impaired procathepsin D mitogenic activity . 
The argument was also supported by experiments showing maintenance of mitogenic 
activity in a proteolytic inactive mutated form of procathepsin D. Besides this, 
enzymatically inactive procathepsin D can be secreted by various cell types including 
macrophages, keratinocytes, mammary epithelial cells and cancer cells of different 
origins, acting as a paracrine and autocrine mitogen on cancer cells, fibroblasts and 
keratinocytes. 
Therefore, it is possible that many proteins would fold correctly only during or 
after interaction with a binding partner, such as chaperones, protein disulfide 
isomerases or even different proteases along a proteolitic cascade. 
 In this study the major goal is to provide basic information for SmCD production 
in E.coli and refolding in large amounts.  This is aimed at future drug screening trials to 
inhibit the proteolitic activity that may lead to novel chemotherapies against 
schistosomiasis. One strategy to refold SmCDs investigated was the use of 
Schistosoma mansonii protein disulfide isomerase (PDI) in order to rearrange disulfide 
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bonds of the aspartic protease as well as provide a chaperone environment able to 
assist refolding. 
1D- Protein Disulfide Isomerases 
  Protein disulfide isomerase (PDI) is a member of the thioredoxin family, 
which is composed of several redox proteins (Dellagi et al, 2002). PDIs also display 
chaperone activity and are highly abundant ER luminal proteins in mammalian and 
yeast cells, essential tools for assisting unfolded or incorrectly folded proteins to their 
native states (Dellagi et al, 2002). Evidence exists that PDIs can serve as potential links 
between thiol–disulfide systems and oxidative protein folding, participating in other ER 
redox systems. The first evidence involves vitamin K epoxide reductase (VKOR), 
responsible for regeneration of vitamin K1, an essential redox cofactor for carboxylation 
of glutamic acid residues. The second evidence is a possible regulatory role in 
NAD(P)H oxidase production of reactive oxygen species in vascular smooth muscle 
cells. Thirdly an intriguing function of certain PDIs is related to homeostasis of the ER 
luminal calcium ion concentration ([Ca2+]ER). Ca2+ pumps and channels in the ER 
membrane are responsible for regulating [Ca2+]ER. In most tissues this function is 
carried out by sarco(endo)plasmic reticulum Ca2+ ATPase isoform 2b (SERCA2b) and 
by inositol 1,4,5- trisphosphate receptor type I (IP3R1). Both proteins are subject to 
regulation by a PDI family member interacting with an ER luminal domain (Appenzeller-
Herzog & Ellgaard, 2007). 
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The overall architecture of PDI comprises (in order from the N-terminus) domains 
a-b-b0-a0-c, where a and a0 are homologous thioredoxin-like domains containing a 
redox active site with the sequence motif WCGHCK. The b and b0 are also thioredoxin-
like but lack the redox active site. The c domain is a C-terminal region rich in acidic 
residues. Sometimes the structure also includes an x interdomain linker comprising 19-
residues linking the b0-a0 domains. PDI structure has a twisted U-shaped molecule 
where e b domain extends the hydrophobic site on b0 and the a and a0 domains faces 
each other in the central cleft. (Dellagi et al,2002 ; Wang & Narayan, 2008). Each 
domain adopts a typical thioredoxin-like fold consisting of a central five-stranded beta 
sheet flanked on each side by two alpha helices forming a  U shaped structure which is 
lined with hydrophobic residues thought to constitute the ligand binding site (Figure 5).  
 
Figure 5: Crystal structure of PDI1P from S. cerevesae, showing the general structure 
of the four thioredoxin fold domains, a, a’,b, b’ and the x-linker region. The active site 
motifs  marked with arrows (adapted from Hatahet, 2007)  
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The relatively weak binding of the PDI domain bb0 to peptides and proteins and 
the large size of its binding pocket with a large hydrophobic surface is consistent with a 
low degree of specificity for ligands. High specificity is not expected because PDI acts 
on many substrates with different primary sequence. This site appears to be responsible 
for the saturable kinetics observed for RNase A folding by PDI, and blocking the site 
strongly inhibits the activity of PDI. (Denisov et al, 2008) 
Crystals of yeast Ppi1p has shown flexibility in its conformation specially related 
to a domain orientation within the whole molecule and this flexibility would tend to 
prevent formation of crystals (Kozlov et al, 2009; Byrne et al,2009). The absence of 
good high resolution structural data for full-length human PDI (despite mammalian PDI 
having been abundantly available for more than 25 years) has been assumed to arise 
from molecular motions (e.g., independent motions of domains), but it could also arise 
from sample heterogeneity due to the existence of multiple conformers or multiple 
states of association (Wallis et al, 2009). 
The catalytic cysteines of PDI are about 50% deprotonated at pH 7.1. Therefore 
redox potentials largely arises from differences in the thiol pK value of the N-terminal 
cysteine, which serves as the primary nucleophile that attacks the disulfide linkages of 
the protein substrate. As a result, the pK of the cysteine thiol provides an indication of 
whether these proteins will act predominantly as oxidants or as reductants under 
physiological conditions (Figure 5). The combination of redox and chaperone-like 
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activities allows PDI to bind to partly folded proteins and catalyze simultaneously protein 
folding and formation of disulfide bond (Hernandez et al, 2008). 
Proteins with thioredoxin fold like PDI generally have two main regions that 
influence their function: the CXXC motif (“redox rheostat”) in the active site and a loop 
containing a cis-proline residue closer to the CXXC motif. Experiments revealed that the 
exchange of X-X dipeptide between two different PDI’s resulted in partially shifted redox 
potential. This is because sequence identity between PDIs for the active site is < 10%, 
making it difficult to compare PDI’s catalysis accurately (Ren et al, 2008; Denisov et al, 
2008). On the other hand, the loop containing the cis-proline residue is well conserved 
and biophysical studies of E.coli thioredoxin and DsbA indicated a significant role in the 
structural stability and modulation of substrate binding and activity of PDI’s (Ren et al, 
2008). 
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Figure 6- Reactions of oxidation, reduction and isomerization catalyzed by PDI. When 
PDI is in the oxidized state, the first reaction is the formation of a mixed disulfide by a 
nucleophilic attack of a thiol substrate (reaction 1). From the mixed disulfide, there are 
three possible options: First option is a nucleophilic attack by a substrate thiol on the 
PDI–substrate mixed disulfide (reaction 2) t resulting in oxidation of the substrate and 
reduction of PDI; The second option is a nucleophilic attack of PDI on the mixed 
disulfide (reaction 3); The third is a nucleophilic attack by a substrate thiol on a 
substrate disulfide (reaction 4), resulting in an isomerization reaction. When PDI is in 
the reduced state, the first reaction is the formation of a mixed disulfide by the 
nucleophilic attack of PDI on a disulfide bond in the substrate (reaction 5). Again, there 
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are three options: The first option is the release of reactants following nucleophilic 
attack by a substrate thiol on the mixed disulfide; The second option is the nucleophilic 
attack of a different substrate thiol on the mixed disulfide, resulting in isomerization 
reaction in the substrate protein (reaction 6). The third is the nucleophilic attack by PDI 
on the mixed disulfide, resulting in reduction of the substrate (reaction 7) (adapted from 
Hatahet et al, 2007). 
Recently, several studies indicated that DsbA, a bacterial homologue of PDI, is 
involved in the biogenesis of the enterotoxin and the toxin-coregulated pilli of Vibrio 
cholera, making it a possible good drug target. DsbA i also catalyzes disulfide bond 
formation in a pili-specific chaperone, PapD in enteropathogenic E. coli. species, It has 
been shown that a PDI-mediated reduction of a disulfide bond of gp120 is required for 
the entry of HIV into the host cells and infection. Recently, it was demonstrated that the 
presence of native PDI on the surface of epithelial cells is required for infection by 
Chlamydia trachomatis, a leading bacterial agent causing sexually transmitted diseases 
(Raturi & Mutus, 2007). 
Also, several Plasmodium sp antigens relevant for virulence and pathogenesis of 
malaria possess a high number of cysteine-residues and P. falciparum has four PDI 
molecules (PfPDI’s) displaying a high degree of diversity in their amino acid sequences, 
structure and the number of thioredoxin-like domains to assist folding of those antigens 
(Mahajan et al 2008). This fact and the fact that homologous and heterologous PDI’s 
have been used to improve the folding of foreign proteins expressed in yeast cells 
raised the perspective that PfPDI’s could be used to improve  folding of several malaria 
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proteins produced via E.coli hosts and used in vaccines with biologically and 
immunologically inferiority to the native parasite antigens. (Mahajan et al 2008). 
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Chapter 2- Materials and Methods 
 Enzymes production 
Aspartic protease from S. mansoni - E.coli production 
  In previous work by Silva, Jr (data not published), cDNA of the proform of the 
aspartic protease proSmCD1 was inserted into the pTBSG1 vector (built on the basis of 
vector pMCSG7, which is based on vector pET30Xa/LIC – Novagen, as shown in 
scheme 1), containing a six histidine tag (His6) on the N-terminus. This vector was 
inserted into E.coli strain BL21 (DE3) pLys-S for the expression of SmCD1 protein. 
 
Scheme 1: Main features of the vector pTBSG and their precursors, pMCSG7 and 
pET30. 
 The newly transformed cells were incubated in 25 ml of Luria-Bertani (LB) media  
with 100 µg/ml ampicillin and 34 µg/ml of chloramphenicol in 125 ml Erlenmeyers in a 
shaking incubator overnight at 200 rpm, 37 °C. The cell s were inoculated into 1000 ml 
of liquid LB medium with the same concentration of antibiotics. The culture was 
incubated for 2 hours, 37 °C and shaking at 200 rpm. Readings of optical density (OD) 
32 
 
at 600 nm were taken until the OD reached 0.4-0.6. Induction of protein synthesis was 
initiated by adding 0.5 mM β-D Isopropyl-1-thiogalactopiranoside (IPTG) and the culture 
was incubated for 4 hours while shaking at 200 rpm at 37 °C.  
  The culture was centrifuged at 10,000xg for 10 minutes at 4 °C and the pellet 
was stored at -80 °C overnight. Cells were resuspended in 25 mM Tris-HCl (pH 8.0)  
disrupted by freezing and thawing followed by 10 min. sonication in a Sonifier 450 
Branson system. Centrifugation of this material for 20 min at 4°C and 10,000xg allowed 
separation of inclusion bodies from the supernatant. Inclusion bodies were stored at -80 
°C. 
Aspartic protease from S. mansoni - SF9 production 
 The cDNA of the proform of aspartic protease SmCD1 was inserted into 
pFastBac1 LIC vector using Bac-to-Bac® Baculovirus Expression System from 
Invitrogen. The vector with the SmCD1 insert was transformed into  E.coli DH10Bac™ 
to be integrated into the baculovirus shuttle vector (bacmid), bMON14272, containing a 
low-copy number mini-F replicon, Kanamycin resistance marker and a segment of DNA 
encoding the LacZ peptide. The bacmid propagates in E.coli DH10Bac™ to form 
colonies that are blue (Lac+) in the presence of a chromogenic substrate such as Blu-
gal or X-gal and the inducer, IPTG. Recombinant bacmids (composite bacmids) are 
generated by transposing a miniTn7 element from a pFastBac™donor plasmid to the 
mini-attTn7 attachment site on the bacmid. The Tn7 transposition functions are provided 
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by a helper plasmid (pMON7124) which encodes a transposase and confers resistance 
to tetracycline.  
 
 
Scheme 2: Main features of the vector pFastBac for insect cell expression, showing 
where ProSmCD was cloned as the gene of interest. 
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  The recombinant E.coli colony is isolated and its bacmid isolated and used to 
transfect SF9 insect cells. An SF9 insect culture of 8 × 105 cells per ml per well with 
>95% viability was allowed to attach to 6 well plates for 30 minutes to achieve  
transfection. After attachment, 1 µg of Bacmid was diluted with 8 µl of Cellfectin 
(Invitrogen) in 100 µl of Grace’s insect medium and kept at room temperature for 30 
minutes. This mixture was dropped into the wells containing SF9 cells with medium and 
kept at 27 °C for 5 hours. Medium was removed and repl aced by Grace’s insect 
medium and plates were kept at 27 °C for another 72 h ours until signs of infection were 
observed under a microscope. Cells were harvested to generate P0 virus stock. In order 
to increase multiplicity of infection (M.O.I.), a P1 recombinant virus stock was generated 
and used for protein expression. 2x107 SF9 cells in 50 ml of medium (Expression 
Systems) were infected with P1 virus stock and incubated in a shaking incubator at 270 
rpm at 27 °C for 7days in a 125 ml Erlenmeyer flask for protein production. Cells were 
harvested after 7 days for protein purification and the process repeated until an M.O.I of 
0.1 was reached with P3 recombinant virus stock. 
 
Proten Disufide Isomerase  from  S. mansoni. 
 The cDNA of S. mansoni protein disulfide isomerase, was inserted into a 
pTBSG1 vector containing a 6 Histidine tag on the N-terminus, and was transformed 
into strain BL21 (DE3) pLys-S for expression in E. coli. The newly transformed cells 
were incubated in 25 ml of Luria-Bertani (LB) media with 100 mg / ml ampicillin and 34 
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mg / ml of chloramphenicol in 125 ml Erlenmeyers in a shaking incubator overnight at 
200 rpm, 37 °C. The cells were inoculated into 1000 ml of liquid LB medium with the 
same concentration of antibiotics. The culture was incubated for 2 hours at 37 °C and 
shaking at 200 rpm. Readings of optical density (OD) at 600 nm were taken until the OD 
reached 0.4-0.6. Induction of protein synthesis was initiated by adding 0.5 mM β-D 
Isopropyl-1-thiogalactopiranoside (IPTG) and the culture was incubated for 4 hours 
while shaking at 200 rpm at 37 °C.  
  The culture was centrifuged at 10000xg for 10 minutes at 4 °C and the cells were 
stored at -80 °C overnight. Cells were then disrupted by freezing and thawing followed 
by sonication in a system Sonifier 450 (Branson). Centrifugation of this material for 20 
min at 4 °C and 20,000 rpm allowed separation of supernatant with soluble protein 
disulfide isomerase from the insoluble materials. Soluble protein was stored in 4 °C in 
50 mM Tris-HCl buffer (pH 8.0) with 20 % glycerol. 
 
Purification by affinity chromatography with immobilized metal IMAC  
 Samples of proteins were placed in His-tag affinity column (Qiagen) previously 
equilibrated with 25 mM Tris-HCl (pH 8.0) and washed once in the same buffer. The 
elution was performed with 25 mM Tris-HCl (pH 8.0) plus 300 mM imidazole. 1 ml 
fractions were collected and the protein concentration of each fraction was determined 
using the Bradford method.  
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Purification of Protein Disulfide Isomerase by ion-exchange in FPLC 
 Samples of protein disulfide isomerase purified from the His-tag affinity column 
were pooled and applied to an ion exchange column (Q-Sepharose-Amershan) in an 
AKTA FPLC system previously equilibrated with 25mm Tris-HCl buffer (pH 8.0) with 
0.15 M NaCl  and 10 mM beta-mercaptoethanol (Buffer A). Elution was performed with 
a gradient using a mixture of Buffer A and Buffer B, consisting of 25 mM Tris-HCl (pH 
8.0) with 1 M NaCl and 10 mM 2-mercaptoethanol. Fractions of 1 ml each were 
collected and the protein concentration of each fraction was determined using the 
Bradford method. 
 
Purification of Protein Disulfide Isomerase by size exclusion in FPLC  
 Samples of protein disulfide isomerase purified from the ion exchange column 
were pooled together in a final concentration of 2mg/ml and applied to a size exclusion 
column (Superdex™ 200 GE) in an AKTA FPLC system previously equilibrated with 25 
mM Tris-HCl (pH 8.0) with 10 mM beta-mercaptoethanol and samples collected in 1 ml 
fractions. The protein concentration of each fraction was determined using the Bradford 
method and each fraction concentration were estimated to be 0.25 mg/ml and 
concentrated to 40 mg/ml using Amicon centrifugal filters of 3,000 MWCO.  
 
Crystallization trials of Protein Disulfide Isomerase  
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 A screening of crystallization conditions was performed with a sample of protein 
disulfide isomerase using several different conditions (presented in screening kits- 
Hampton Index, Wizard Crystal Screen I, II, III, IV) and the sitting drop technique. Plates 
of 96 wells were filled with 1 ml in each big well and with 0.1 ml in each small well with 
varying solution conditions as per the kits.  A 0.5 µl of protein disulfide isomerase 
sample (40mg/ml) was added to each small well and plates were tapped and placed at 
either 4 °C or room temperature to allow crystal growth. Plates were periodically 
checked under a microscope to observe crystal growth. 
 
Electrophoresis Sodium Dodecyl Sulfate Polyacrylamide Gel  (SDS PAGE) 
  The polyacrylamide gel electrophoresis in the presence of sodium dodecyl 
sulfate (SDS-PAGE) was performed in 12% polyacrylamide gels as described by 
Laemmli (1970). Aliquots of purified aspartic proteases were mixed with an equal 
volume of sample buffer (0.187 M Tris-HCl, pH 7 + 0.2% SDS (w/v) + 1% Bromophenol 
blue (w / v) + 27% glycerol (v/v) + 5.0% (v/v) β-mercaptoethanol and heated for 3 min at 
100°C. Gels were electrophoresed at 100 V for 90 min utes using a Mini-Protean III (Bio-
Rad, USA) gel apparatus. The molecular weights of proteins were determined by 
comparing the migration of the protein with those of molecular weight markers (Sigma 
Chemical, USA). Proteins were stained using Coomassie Brilliant Blue G250.  
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Western Blots 
 Proteins separated in SDS PAGE gels were transferred to Immobilon PVDF 0.45 
µm membranes (Millipore) using an XCell II Blot Module overnight at 10 V.  Immobilon 
PVDF membranes were treated with KPL Western blot kit for overnight blocking and 
washing.   
 
Refolding of aspartic protease from S. mansoni  produced in E.coli 
  Initial refolding tests were performed using a slow dialysis method. This 
experiment was performed using aliquots of 1 mg/ml of SmCD1 diluted one hundred 
fold in 25mm Tris-HCl (pH 8.0) containing different chaotropic agents such as 20% 
glycerol, 0.5 M sucrose, 1M LiCl, 1M NaBr, 5mM GSSH/GSH, 1M arginine. These 
solutions were placed inside SpectraPore Dialysis membrane MWCO 3,500 and 
dialysed against 25 mM Tris-HCl (pH 8.0) at room temperature or 4° C overnight.  
In another experiment an attempt was made to refold the protein using an Ni-
NTA affinity resin previously equilibrated with 25 mM Tris-HCl (pH 8.0) with 500 mM 
NaCl, 8 M urea and 2.5 mM β-mercaptoethanol, in 4 °C. SmCD1 samples were mixed 
up for two hours with this resin and then the resin was washed out with 25 mM Tris-HCl 
(pH 8.0) with 500 mM NaCl, 2.5 mM β-mercaptoethanol and decreasing urea 
concentrations of urea from 6 M to 0 M. After the washing step, protein was eluted in 
fractions of 1 ml in the same buffer containing 250 mM imidazole and 20% glycerol.  
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PDI activity assays  
 Assays was performed using a modification to Sigma’s protocol, using 0.75 ml of 
a cocktail made of 10 mM Na-phosphate (pH 7.0), 100 mM DTT, 100 mM Na-EDTA, 
incubated with 0.25 ml of different concentrations of insulin (100 µg/ml, 250 µg/ml, 500 
µg/ml). The mixtures were incubated for 10 min at 25°C, 37°C and 45°C. After 
incubation, 10 µl of protein disulfide isomerase were added into this solution containing 
insulin and turbidity at 650 nm of solution was monitored at 5 minute intervalsthe  until 
30 min. The same assay was used for refolding of SmCDs. 
 
SmCD1 activity assays 
 SmCD1 proteolysis assays were performed using the method described by 
Brindley et al, (2001) for the insect cell-derived enzyme. SmCD1 was diluted to 100 
µg/ml in 0.1 M citrate (pH 3.5) and incubated at 37 °C with and without human 
hemoglobin for 1, 2, 4, 8, 12, 24, 48 and 72 hours. Results were visualized in 12% SDS 
PAGE gels following electrophoresis. 
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Chapter 3- Results and Discussion  
 
3.1-Refolding  SmCDs. 
 ProSmCD1 cDNA was inserted into pTBSG1 vector with a six histidine tag (His6) 
on the N-terminus. This vector was inserted into E.coli strain BL21(DE3)pLysS and 
expression was carried at 200 rpm at 37 °C with IPTG Induction. Cells were harvested 
by centrifugation at 10.000 rpm at 4°C for 15 min and resuspended in 50 ml of 25 mM 
Tris-HCl pH 8.0 and then submitted to sonication to be lised. Cell lisates were 
centrifuged in 20.000 rpm at 4°C for 20 min and pellet of inclusion bodies were 
collected, resuspended and stored at -80 °C in 25 mM Tri s-HCl pH 8.0 with 20% 
glycerol. Figure 7 shows the inclusion body protein solubilized in urea and SDS or SDS 
alone, indicating that it is obtained in a significantly purified form prior to further 
purification. 
 In this study two main strategies were used in attempts to obtain soluble, 
correctly folded and active proSmCD protein from heterologous expression in E. coli. 
The functional state of the folded protein was determined by examining its ability to self 
cleave and/or cleave human hemoglobin. The first strategy involved dissolution of 
inclusion bodies followed by refolding assays manipulating folding conditions. The 
second strategy involved covalent attachment of a solubilizing protein to the proSmCD 
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protein in order to confer greater solubility such as the Maltose Binding Protein (MBP) 
(Baneyx & Mujacic, 2004, Sahdev et al., 2008).  
 As part of the first strategy, SmCD1 inclusion bodies were subjected to a variety 
of ways to disrupt non-covalent forces that result in loose protein-protein interactions 
leading to formation of inclusion bodies (Arakawa, 2007). This involved chemical agents 
(chaotropes) such as urea followed by several different formulations of solutions 
containing combinations of compounds able to favors refolding (cosmotropic). The 
simplest consisted of diluting SmCD1 inclusion bodies in an appropriate buffer 
containing a combination of amino acids (arginine), polyols (glycerol), alcohols, / 
reducing agents (DTT, Glutathione), EDTA , salts from the Hofmeister series, sugars 
(glucose) and detergents (DPPC) (Qoronfleh et al., 2007).   
     Two folding approaches were tested: dialysis, involving the slow and gradual 
withdrawal of the chaotrope used to dissolve the inclusion bodies and replacing it with 
the chemical agents, and chromatography consisting of an affinity resin that acts as a 
site of nucleation in order to allow refolding of the protein while a solvent with a 
combination of refolding agents is passed through. However, all of these combinations 
lead to a non auto-activate form of the protein that is unable to show self-clevage. An 
example of such a trial is shown in Figure 8.  In this experiment, proSMCD 1 inclusion 
bodies were solubilized in 8 M urea then dialyzed against Tris buffer containing NaBr (1 
M), LiCl (1 M) or urea (8 M) to keep the folded protein from aggregating.  Shifting the pH 
from 8.0 to 3.5 is expected to induce self cleavage of the protein to an expected 45 kDa 
form however no such cleavage was observed in this and similar experiments. This 
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suggests that either the protein is not correctly folded or that activation via a pH shift 
requires some additional cofactor. 
 
 
 
 
Figure 7: Pro SmCD1 inclusion bodies treated with 8 M Urea. Lanes 1: urea-
solubilized proSmCD1 inclusion bodies kept at room temperature in 8 M Urea and 25 
mM Tris-HCl (pH 8.0); lane 2: proSmCD1 inclusion bodies solubilized in sample buffer; 
Lane 4, Fisher E-z Run Protein Marker.  
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Figure 8: Pro SmCD1 inclusion bodies were solubilized in 25 mM Tris-HCl pH 
8.0 with 8 M urea, dialyzed to maintain  8M Urea (Lanes 2 and 3) or 1 M NaBr (Lanes 4 
and 5,) or to exchange 8M urea with 1 M LiCl (Lanes 6 and 7) to enhance solubility and 
dispersion.  In some cases the pH was shifted to 3.5 by adding an equal volume of 
sodium citrate (pH 3.5) 2, 4 and 6).  Lane 1: urea-solubilized proSmCD1 inclusion 
bodies (overloaded); Lane 28 M urea kept at pH 3.5;  Lane 3: inclusion bodies in the 
presence of 8 M urea kept at pH 8.0; Lane 4: inclusion bodies in the presence of 1 M 
NaBr kept at pH 3.5; Lane 5: inclusion bodies in the presence of 1 M NaBr kept at pH 
8.0; Lane 6: inclusion bodies in the presence of 1 M LiCl kept at pH 3.5; Lane 7: 
inclusion bodies in the presence of 1 M LiCl kept at pH 8.0; lane 8, Fisher E-z Run 
Protein Markers.  
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3.2  Use of Protein Disulfide Isomerase  
 
  The genome of Schistosoma mansonii encodes a protein disulfide isomerase, 
responsible for ensuring the correct formation of disulfide bridges as well as assisting 
the correct folding of proteins using an intrinsic chaperone domain (FInkenEigen et al, 
2007). Therefore, PDI may be required for folding of SmCD proteins since these 
aspartic proteases have disulfide bonds that could be rearranged in a variety of ways.  It 
is also possible that the PDI is required to assist with folding of the SmCD proteins.   
To examine the potential role of PDI in SmCD folding, the cDNA of S. mansoni 
protein disulfide isomerase was cloned and inserted in a PTBSG vector and expressed 
in E. coli host cells as described in Chapter 2. PDI was expressed in soluble form and 
readily purified by Ni-affinity chromatography.  Further purification to apparent 
homogeneity (as judged by SDS gel electrophoresis, not shown) was achieved by ion 
exchange chromatography (Figure 9) and size exclusion chromatography (Figure 10).  
The recombinant PDI was active in refolding of insulin, a classical assay for this 
class of enzyme, as described previously and in the Chapter 2 (Figure 11). In these 
experiments, 0.75 ml of a cocktail made of 10 mM Na-phosphate (pH 7.0), 100 mM 
DTT, 100 mM Na-EDTA, incubated with 0.25 ml of different concentrations of insulin 
(100 µg/ml, 250 µg/ml, 500 µg/ml). This solution was incubated for 10 min at 25°C, 37°C 
and 45 °C. After incubation, 10 µl of protein disulfi de isomerase were added into this 
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solution containing insulin and turbidity at 650 nm of solution was monitored from 5 to 5 
minutes until 30 min.  
 In further experiments, folding trials to observe self-proteolysis of Pro-SmCD 
enzymes were undertaken in the presence of different concentrations of PDI. However, 
none resulted in proSmCD1 auto-activation. A typical experiment is shown in Figure 12. 
 The lack of activation may indicate that the Schistosomal PDI is not used as a 
chaperone or isomerase to assist correct folding of SmCDs or there is still lacking an 
external factor such as another protease for SmCD activation. 
Analysis of ion exchange and size exclusion chromatography led to the conclusion that 
Schistosoma mansoni PDI was sufficiently well purified to attempt crystallization trials. 
Extensive screening of crystallization conditions was performed using conditions 
presented in screening kits- Hampton Index, Wizard Crystal Screen I, II, III, IV- using the 
sitting drop technique in 96 well plates tapped and placed at either 4 °C or room 
temperature.  However, PDI crystals were not obtained.  One possible reason is that this 
enzyme has the same high degree of flexibility in the “a” domain as other members of 
the PDI family which make formation of crystals a difficult task (Kozlov et al, 2009) 
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Figure 09: PDI purification by ion-exchange chromatography. A 10 ml sample of protein 
disulfide isomerase purified from the Ni-affinity column was applied to an ion exchange 
column (Q-Sepharose-Amershan) in an AKTA FPLC system previously equilibrated with 
25 mM Tris-HCl buffer (pH 8.0) with 0.15 M NaCl and 10 mM beta-mercaptoethanol 
(Buffer A).  Elution was performed with a gradient using a mixture of Buffer A and Buffer 
B, consisting of 25 mM Tris-HCl (pH 8.0) with 1 M NaCl and 10 mM beta-
mercaptoethanol. 
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Figure 10: PDI purification by size exclusion chromatography. PDI fractions from the ion 
exchange column step (Figure 9) were pooled, concentrated in a Centricon 30 kDa filter 
column and a volume of 2 ml applied to a size exclusion column (Superdex™ 200 GE) 
in an AKTA FPLC system previously equilibrated with 25 mM Tris-HCl (pH 8.0) with 10 
mM beta-mercaptoethanol. 1 ml fractions were collected.  
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Figure 11: Protein Disulfide Isomerase activity. The assay was performed using a 
modification to Sigma’s protocol, using 0.75 ml of a cocktail made of 10 mM Na-
phosphate (pH 7.0), 100 mM DTT, 100 mM Na-EDTA, incubated with 0.25 ml of 
different concentrations of insulin (100 µg/ml, 250 µg/ml, 500 µg/ml). This solution was 
incubated for 10 min at 37°C for 10 min. After incuba tion, 10 µl of protein disulfide 
isomerase were added into each solution and turbidity at 650 nm of solution was 
monitored at 5 minute intervals for 30 min.  
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Figure 12: SmCD1 refolding assay with PDI. ProSmCD1 inclusion bodies were 
solubilized in urea and dialyzed against 25 mM Tris-HCl and 20% glycerol.  PDI was 
added at the end of the dialysis step.  Lane 1, without PDI (55 kDa) as a control at pH 
8.0; Lane 2: proSmCD1 without PDI as a control at pH.3.5; Lane 3: with PDI at pH 8; 
Lane 4: Same as lane 1, but at pH 3.5; Lane 5, Fisher E-z Run Protein Marker.  No 
apparent 35 kDa band was present indicating the lack of SmCD1 activation.  
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3.3- SmCD1 expression in insect cells (SF9 cells) 
Previous reports of SmCDs and related parasite’s proteases (as Ac-APR-1 and 
Na-APR-1) shows their ability to be expressed in a soluble and active manner were in 
insect cells (Brindley et al.2001, Verity et al, 2001, Williamson et al, 2003). In those 
cases, SF9 cells were used to expand the vector containing aspartic protease cDNA to 
be transfected in Trichoplusia ni High Five cells (HiFive TN cells) for protein production. 
The purification steps used in this case included as a first step a typical affinity 
chromatography with the most common inhibitor of aspartic proteases, pepstatin. 
In this study, proSmCD1 was expressed in SF9 cells as described in Chapter 2 
and purified from the soluble cell lysates using a Ni- affinity column. Analysis by 
Western blot revealed that a polypeptide with a larger than expected molecular weight 
(75 KDa) was produced at very low levels in the insect cells.  Although visible during the 
immunodecoration procedure the image was too faint to properly capture using the 
available camera.  The fact that the band was larger than expected suggests that the 
expressed protein was hyperglyscosyled. This result, which is contrary to the one 
achieved by Brindley et al, 2001, may be due to differences between the HiFive TN cells 
and SF9 cells used in this study. Further investigation is needed to clarify the difference 
and in order to obtain SmCDs in a soluble and active form from insect cells.  
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3.4-MBP attachment for soluble SmCD2 expression.   
As a final attempt to obtain active SmCD protease a maltose binding protein 
(MBP) adduct was incorporated into the N-terminal end of the SmCD1 gene.  A His6 tag 
was added to the N-terminal end of the MBP for affinity purification.  In this case, the 
MBP tag was attached to the mature form of the SmCD2 protein rather than the pro 
form. This construct was prepared by Dr. Silva. Over-expression of the construct 
resulted in production of considerable amounts of the MBP-SmCD in soluble form as 
indicated in Figure 13 following purification by Ni-affinity chromatography. Examination 
of the gel profile indicated the presence of several lower molecular bands in addition to 
the 75 kDa MBP-SmCD protein.  Since this system routinely results in highly purified 
protein the data suggest that the lower molecular weight bands may result from self 
cleavage by the MBP-SmCD protein.  This was the first piece of evidence that could be 
obtained for the presence of an active recombinant SmCD protein.   
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Figure 13: Purification of MBP-SmCD2. E.coli BL21 cells transformed with the 
MBP-SmCD2 DNA were grown to mid log phase and induced with IPTG as described in 
Chapter 2.  Cells were harvested and lysed by sonication.  The soluble cell fraction 
following lysis was applied to a Ni-affinity column.  Lane1, Promega Protein Marker; 
Lane 2, cell lysate; Lane 3, soluble cell fraction; Lane 4, column flow through material; 
Lane 5: protein eluted with 300 mM imidazole.  
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3.5- Discussion 
 The expression of SmCD protein In E.coli resulted in formation of inclusion 
bodies, insoluble protein aggregates. This fact is not a surprise since the appearance of 
insoluble aggregates is common when E.coli is used as a host for helminth or 
mammalian proteins (Sahdev et al., 2008). Although inclusion body formation can be 
useful in terms of ease of purification, the process of solubilization and refolding can be 
laborious and may lead to a low percentage of active, properly folded protein (Sahdev et 
al., 2008).   
Virtually all polypeptide chains can form insoluble aggregates as well as soluble 
forms depending on the physical factors within the environment that govern protein 
folding, such as temperature, pH, chemical composition, pressure and viscosity. Each 
cell has specific ways to modulate these factors, using organic and inorganic 
compounds, chaperone systems and compartmentalization. Inclusion bodie refolding 
processes attempt to mimic those conditions in vitro (Jahn & Radford, 2008; Bolen & 
Rose, 2008; Frauenfelder et al., 2006).  
 Extensive refolding trials aiming at recovering a self activating functional 
protease from ProSmCD inclusion bodies were performed under numerous different 
conditions.  Although soluble forms of this protein were obtained, the protein was either 
not correctly folded for expression of its proteolysis function or this function requires an 
external factor or partner to be active.  
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A Schistosoma genome project done in early 1990’s decade suggests the presence of 
at least one protein disulfide isomerase (PDI)in S. mansonii. This is important not only 
because it can be the partner required for SmCDs refolding (these proteins contains 
disulfide bridges that can be rearranged by PDI, but also because PDI can be 
considered a possible drug target itself, since it is involved in folding of toxins and other 
related infective proteins of pathogenic bacteria (enteropathogenic E. coli and Vibrio 
cholerae). However, PDI crystals for structural studies were not obtained in the conditions and 
it is possible that this enzyme have the same high degree of flexibility in the a domain as others 
of PDI family which turn formation of crystals a difficult task. Also, although S. mansoni PDI 
obtained is active in rearrange insulin disulfide briges, its presence did not lead to 
SmCDs activation which may indicate that this PDI is not used as a chaperone or 
isomerase to assist correct folding of SmCDs. 
 The external factor or partner hypothesis is also supported by the observation 
that the mature form of SmCD2 expressed with the MBP tag, a partner that helps 
increase solubility, may be active (further investigation is currently underway). However, 
there are other alternative explanations for the lack of function in our experiments with 
the pro form of SmCD1.  In recent years, several authors published papers about other 
functions than proteolysis of human cathepsin D. Beaujouin et al, 2006, for example, 
indicates the possible role of non proteolitic (inactive for proteolysis) cathepsin D in 
apoptosis, which could possibly be related with similar phenomena in exchange of life 
stages of Schistosoma sp., Vashishta et al, 2005 discuss the possible dual role of 
cathepsin D, as a protease and as a ligand factor crucial for cancer metabolic pathways. 
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Therefore, since SmCDs are cathepsin D like proteins, all the soluble forms achieved in 
this work may be microstates of the protein related to other functions than a proteolytic 
function.  
 On the other hand, invertebrates like the helminth Schistosoma seem to have a 
cascade for degradation of proteins for nutritional purposes. Although this cascade 
seems to occur in a non-coordinated and redundant sequence of events, in contrast to 
vertebrates (Delcroix et al., 2006), there may be some sequence of events required for 
activation of the SmCD proteases. An external factor required for activation of protein 
degradation may be the most reasonable scenario for SmCDs and their proteolysis 
activity. Rather than constitute a problem, the combination of this two possible 
explanations may increase the importance and appeal of SmCDs as possible drug 
targets against schistosomiasis. 
 In conclusion, we have obtained evidence that mature form of SmCD2 attached 
to the MBP may be proteolytically active.  This provides a promising avenue of research 
to developing an assay suitable for identifying potential lead compounds, through 
screening of molecular libraries, as a basis for developing new drugs to target 
Schistosomiasis.  
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